1. Home
  2. AGIO vs HMN Comparison

AGIO vs HMN Comparison

Compare AGIO & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$33.11

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Horace Mann Educators Corporation

HMN

Horace Mann Educators Corporation

HOLD

Current Price

$50.47

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
HMN
Founded
2007
1945
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.1B
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
AGIO
HMN
Price
$33.11
$50.47
Analyst Decision
Buy
Buy
Analyst Count
8
3
Target Price
$38.88
$47.33
AVG Volume (30 Days)
1.2M
231.2K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
3.05%
EPS Growth
N/A
57.26
EPS
N/A
2.01
Revenue
$43,011,000.00
$1,701,400,000.00
Revenue This Year
$76.75
$6.91
Revenue Next Year
$170.73
$3.41
P/E Ratio
N/A
$25.08
Revenue Growth
N/A
6.66
52 Week Low
$22.24
$41.29
52 Week High
$46.00
$55.56

Technical Indicators

Market Signals
Indicator
AGIO
HMN
Relative Strength Index (RSI) 44.93 42.38
Support Level $32.47 $41.94
Resistance Level $36.07 $53.34
Average True Range (ATR) 1.31 1.41
MACD 0.18 -0.30
Stochastic Oscillator 50.43 8.90

Price Performance

Historical Comparison
AGIO
HMN

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.

Share on Social Networks: